Financial overview
AcuCort financial report data and keyfigures. History for income statement, balance sheet and cash flow.
Description
AcuCort develops and commercializes Dexa ODF - a drug in the form of a fast-dissolving film to apply to the tongue, based on a well-known glucocorticoid - dexamethasone. In the development of Dexa ODF, the benefits of the well-used and documented substance dexamethasone and the fast-dissolving film have been combined in a product that is tailored for quick availability and relief in emergency situations. AcuCort will develop and commercialize Dexa ODF using a global network of licensees and / or distributors. AcuCort will identify, develop and commercialize complementary smart drugs that have a relatively short time to launch and are based on existing substances.